What You Should Know:
– Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new partnership with Mira Precision Health Inc.
– This collaboration aims to advance OCB’s…
Continue Reading
Portal Access, an oncology-focused medical device startup, closed a $7 million Series A financing round.The company said that more than 80% of the round was led by U.S. physician investors, including oncologists, interventional radiologists,…
Continue Reading
We developed a practical framework to construct digital twins for predicting and optimizing triple-negative breast cancer (TNBC) response to neoadjuvant chemotherapy (NAC). This study employed 105 TNBC patients from the ARTEMIS trial (NCT02276443, registered…
Continue Reading
BREAKTHROUGH EXPANSION FOR PROSTATE CANCER THERAPY
Novartis has announced a significant development in prostate cancer treatment with the FDA‘s expanded approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan). This radioligand therapy is now available for…
Building accurate prediction models and identifying predictive biomarkers for treatment response in Muscle-Invasive Bladder Cancer (MIBC) are essential for improving patient survival but remain challenging due to tumor heterogeneity, despite numerous related studies. To…
Continue Reading
Up to 8% of cancer patients refuse chemotherapy because they don’t want to lose their hair. Of course, hair loss can cause immense damage to a person’s self-esteem — but it can also strip…
Continue Reading
Language in Healthcare: Khayat stresses the need for a language shift to change mindsets in healthcare, highlighting that words shape reality. She proposes retiring overused terms like “innovation,” “patient-centered,” and “telemedicine,” advocating instead for…
Continue Reading
Prescribing cancer treatment at South Australia’s flagship hospital Royal Adelaide Hospital has gone digital. The electronic cloud-based system called iQemo is now live at RAH, whose Cancer Day Centre delivers 17,000 cancer treatments to South…
Continue Reading
Background: As the most malignant type of cancer in the female reproductive system, ovarian cancer (OC) has become the second leading cause of death among Chinese women. Chemotherapy is the main treatment for OC…
Continue Reading
Health tech firm System C has announced the strategic acquisition of CIS Oncology, marking a significant expansion of its medicines management offerings.
Once integrated, System C customers will be able to manage their entire prescription…
